JP2019517511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517511A5 JP2019517511A5 JP2018563090A JP2018563090A JP2019517511A5 JP 2019517511 A5 JP2019517511 A5 JP 2019517511A5 JP 2018563090 A JP2018563090 A JP 2018563090A JP 2018563090 A JP2018563090 A JP 2018563090A JP 2019517511 A5 JP2019517511 A5 JP 2019517511A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tumor
- months
- expression pattern
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 15
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 15
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims 6
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims 6
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022146466A JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345658P | 2016-06-03 | 2016-06-03 | |
| US62/345,658 | 2016-06-03 | ||
| PCT/US2017/035798 WO2017210624A1 (en) | 2016-06-03 | 2017-06-02 | Anti-pd-1 antibody for use in a method of treating a tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146466A Division JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517511A JP2019517511A (ja) | 2019-06-24 |
| JP2019517511A5 true JP2019517511A5 (https=) | 2020-07-09 |
Family
ID=59067919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563090A Pending JP2019517511A (ja) | 2016-06-03 | 2017-06-02 | 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 |
| JP2022146466A Pending JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A Pending JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146466A Pending JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A Pending JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20200325226A1 (https=) |
| EP (1) | EP3464369A1 (https=) |
| JP (3) | JP2019517511A (https=) |
| KR (3) | KR20230118713A (https=) |
| CN (1) | CN109476753A (https=) |
| WO (1) | WO2017210624A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| SMT202500282T1 (it) | 2015-11-18 | 2025-09-12 | Bristol Myers Squibb Co | Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4 |
| KR20240149982A (ko) * | 2017-06-01 | 2024-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 종양을 치료하는 방법 |
| WO2019157124A1 (en) * | 2018-02-08 | 2019-08-15 | Bristol-Myers Squibb Company | Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors |
| SG11202007590TA (en) | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| JP2021513540A (ja) * | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| WO2019207030A1 (en) * | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
| WO2020139941A1 (en) * | 2018-12-27 | 2020-07-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Treatment of stk11-loss cancers |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| BR112022003163A2 (pt) * | 2019-08-19 | 2022-05-17 | Pandion Operations Inc | Imunotolerância alvejada com um agonista de pd-1 |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| EP4387104A1 (en) | 2022-12-13 | 2024-06-19 | LX Semicon Co., Ltd. | Analog-to-digital converter and semiconductor device having the same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| SMT202100065T1 (it) * | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) * | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| JP6666905B2 (ja) * | 2014-05-29 | 2020-03-18 | スプリング バイオサイエンス コーポレーション | Ｐｄ−ｌ１抗体及びその使用 |
| SG10201807625PA (en) * | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
-
2017
- 2017-06-02 CN CN201780048321.0A patent/CN109476753A/zh active Pending
- 2017-06-02 KR KR1020237026427A patent/KR20230118713A/ko not_active Ceased
- 2017-06-02 KR KR1020187038120A patent/KR20190015408A/ko not_active Ceased
- 2017-06-02 JP JP2018563090A patent/JP2019517511A/ja active Pending
- 2017-06-02 US US16/306,380 patent/US20200325226A1/en not_active Abandoned
- 2017-06-02 WO PCT/US2017/035798 patent/WO2017210624A1/en not_active Ceased
- 2017-06-02 KR KR1020257022183A patent/KR20250107295A/ko active Pending
- 2017-06-02 EP EP17730636.2A patent/EP3464369A1/en active Pending
-
2022
- 2022-03-21 US US17/699,949 patent/US20220315657A1/en not_active Abandoned
- 2022-09-14 JP JP2022146466A patent/JP2022188071A/ja active Pending
-
2025
- 2025-02-14 JP JP2025022545A patent/JP2025081454A/ja active Pending
- 2025-05-20 US US19/213,805 patent/US20250382368A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517511A5 (https=) | ||
| Zhao et al. | Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo | |
| Laderian et al. | CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| Flaig et al. | A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients | |
| Dhillon | Palbociclib: first global approval | |
| Jhaveri et al. | Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions | |
| JP2019517498A5 (https=) | ||
| JP2019517504A5 (https=) | ||
| Villanueva et al. | A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study | |
| JP2018508516A5 (https=) | ||
| JP2019517512A5 (https=) | ||
| Lu et al. | Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial) | |
| JP2019521087A5 (https=) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2019517505A5 (https=) | ||
| JP2019536805A5 (https=) | ||
| JP2019503365A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2022533578A5 (https=) | ||
| JP2018512391A5 (https=) | ||
| JP2019530713A5 (https=) | ||
| Novello et al. | A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer | |
| Rugo et al. | A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer | |
| Rosenthal et al. | A Phase Ib Study of the combination of Aurora Kinase Inhibitor alisertib (MLN8237) and bortezomib in Relapsed or Refractory Multiple Myeloma | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus |